Alerta

一种pH驱动协同精氨酸诱导米糠蛋白自组装纳米颗粒包埋脂溶性多酚的方法

Resumen de: CN121337007A

本发明属于植物蛋白包埋生物活性物质领域，提供了一种pH驱动协同精氨酸诱导米糠蛋白自组装纳米颗粒包埋脂溶性多酚的方法。通过调节pH促使米糠蛋白自组装形成纳米颗粒，包埋芦丁等脂溶性多酚；利用精氨酸中氨基、羧基、胍基与多酚通过静电、氢键及疏水作用结合，调控蛋白二级/三级结构，增强其与多酚的界面亲和力，改善纳米颗粒溶解性和稳定性。该方法无需有机溶剂，绿色安全，所得米糠蛋白‑芦丁纳米颗粒包埋率超90%，负载量达23.4%，且芦丁在紫外线照射下稳定性良好，适用于生物活性物质的绿色高效包埋。

一种用于抗肿瘤的脂质体

Resumen de: CN121338010A

本发明涉及一种用于抗肿瘤的脂质体。具体地，本发明提供一种单唾液神经节苷酯用途，用于制备纳米颗粒的纳米材料，所述纳米材料用于消除纳米颗粒的蛋白冠。本发明发现单唾液神经节苷酯作为纳米颗粒的纳米材料，能够消除纳米颗粒的蛋白冠，克服蛋白冠对纳米颗粒和纳米颗表面修饰的配体的掩盖作用。此外，本发明还开发一种对肿瘤具有优异治疗效果的脂质体。

一种改性超支化聚赖氨酸及其制备方法和应用

Resumen de: CN121343157A

本发明涉及生物医药技术领域，提供一种基于改性超支化聚赖氨酸(HPL)的核酸递送载体、制备方法和应用，所述改性HPL是通过氨基‑环氧开环反应、Michael加成反应及氨基‑磷戊烷开环反应，分别将1,2‑环氧化合物、丙烯酸酯以及烷基化二氧磷杂环戊烷等小分子化合物引入HPL三维骨架，构建出具有高效转染性能的核酸递送载体。本发明中所述HPL的制备方法简单、价格低廉，是一种生物相容性极好的合成高分子材料。本发明中所述极简一步法的合成策略，一方面可以引入适当长度的疏水链段，从而提高其细胞摄取及跨膜转运能力，另一方面可将HPL上的伯胺转化为仲胺或叔胺，从而提高其内涵体逃逸能力。

一种多酚P2X7抑制剂功能化益生菌及其应用

Resumen de: CN121337763A

一种功能化益生菌系统，其中包括由如下(A)至(C)组成的复合物1：(A)聚合物载体，所述聚合物载体包括聚合物骨架(A1)和键合在所述聚合物骨架(A1)上的苯硼酸端基(A2)，所述聚合物骨架(A1)为透明质酸或其盐中的至少一种；(B)多酚类P2X7抑制剂；和，(C)益生菌；其中，所述(A)和(B)形成复合物2，所述复合物2在全部或至少部分所述益生菌表面形成一层功能修饰层。本发明的功能化益生菌系统，具有P2X7抑制性能和高肠道定植效率，能够抗炎、调节机体免疫以及调控患者肠道菌群，适用于治疗溃疡性结肠炎等炎症性肠病。

一种用于视网膜递送mRNA的脂质纳米颗粒及其制备方法和应用

Resumen de: CN121338044A

本发明公开了一种用于视网膜递送mRNA的脂质纳米颗粒及其制备方法和应用。所述脂质纳米颗粒包含可电离脂质、中性磷脂、胆固醇和PEG化脂质；其中，所述可电离脂质由SM‑102和NT‑O14B组成；SM‑102、NT‑O14B、中性磷脂、胆固醇和PEG化脂质之间的摩尔比为（59.5‑63）：（7‑10.5）：（8‑12）：（16.4‑20.6）：（1.4‑1.6）。与经典LNP配方相比，本发明提供的LNP能够高效递送mRNA至视网膜，并通过小窝蛋白介导的内吞和巨胞饮途径被视网膜色素上皮细胞特异性摄取。体内外实验证实，该LNP可显著提高mRNA在视网膜中的递送效率和功能性蛋白表达水平，且生物相容性良好。本发明为遗传性视网膜疾病（如Leber先天性黑朦）的mRNA治疗提供了一种高效、安全的非病毒递送系统。

一种具有骨靶向性负载连翘酯苷A的外泌体及其制备方法和应用

Resumen de: CN121337764A

本发明公开了一种具有骨靶向性负载连翘酯苷A的外泌体及其制备方法和应用，涉及生物医药技术领域，制备方法，包括以下步骤：分离培养骨髓间充质干细胞，并通过分子克隆技术过表达GLG1得到GLG1‑BMSCs；通过超速离心法收集GLG1‑BMSCs的外泌体GLG1‑Exos；通过超声法联合挤压法将连翘酯苷A装载入外泌体得到GLG1‑Exos‑FTA。本发明负载中医药活性成分连翘酯苷A，将连翘酯苷A靶向性地递送到骨髓，达到预防和改善糖尿病骨质疏松的作用；其靶向性作用能够增强连翘酯苷A的生物利用度，同时增加抗糖尿病骨质疏松的疗效。实验表明，GLG1‑Exos‑FTA的连翘酯苷A装载率达36.9%，粒径分布峰值为122.4 nm，具备典型外泌体特征和骨靶向性，能显著改善糖尿病骨质疏松小鼠的骨微结构。

核酸送達用の新規なイオン化可能脂質化合物

Resumen de: CN120693317A

Novel ionizable lipid compounds, compositions comprising such ionizable lipid compounds, and related methods of use thereof are disclosed. Nanoparticle compositions comprise novel lipids and additional lipids, such as phospholipids, structural lipids, and PEG lipids. The nanoparticle composition also comprises a bioactive agent, such as siRNA or mRNA, which can be used to deliver the bioactive agent to an individual in need thereof.

免疫調節系としてメソポーラスシリカロッドを使用したサイトカインの腫瘍間送達および腫瘍内送達

Resumen de: WO2024148364A1

Embodiments of the invention include methods of treating conditions that are ameliorated by stimulating an immune response. In aspects, the methods include injection of mesoporous silica rods (MSRs) at or near an affected tissue. The MSRs can include a cytokine (e.g., IL-2 or IL-12) and/or an adjuvant. The MSRs can induce an innate immune response to treat cancer, infection and other ailments. The methods can include administering an additional medicament such as an immune checkpoint inhibitor.

眼障害の治療のための薬物コンジュゲート

Resumen de: US2025387503A1

The present invention relates to drug conjugates or pharmaceutically acceptable salts thereof comprising hyaluronic acid (HA) hydrogel microspheres, pharmaceutical compositions and methods of using such conjugates for treatment of ocular disorders, and methods of making the conjugates.

TRAITEMENT PAR PHOTOTHERMIE PLASMONIQUE DES CANCERS CUTANES PRESENTANT DES LESIONS ETENDUES EN UTILISANT DES NANOPARTICULES D’OR

Resumen de: FR3164393A1

L’invention se rapporte au domaine du traitement des tumeurs cutanées. Plus particulièrement, l’invention concerne l’utilisation de nanoparticules d’or pour traiter les tumeurs cutanées dont le volume est supérieur ou égal à 500 mm3. L’invention repose sur une administration de nanoparticules d’or directement dans la tumeur suivie d’une irradiation laser proche de l’infrarouge. La combinaison des nanoparticules d’or et de la photothérapie plasmonique, en traitement répété à 11 à 17 jours d’intervalle, permet une disparition complète d’une tumeur cutanée avec lésion étendue, sans récidive.

核酸分子

Resumen de: CN120957744A

The present disclosure relates to a nucleic acid molecule comprising a 5 '-UTR and/or 3'-UTR sequence that yields a high level of translation. Aspects of the disclosure further relate to nucleic acid molecules suitable for use as vaccines for the treatment and prevention of infectious diseases, including those caused by coronavirus, compositions comprising the nucleic acid molecules, and methods of treating or preventing infectious diseases.

イオン化脂質およびそれを含むナノ粒子

Resumen de: CN120693153A

In some embodiments, one or more ionizable lipids and lipid nanoparticles are provided, the lipid nanoparticles including the ionizable lipids and further encapsulating a polynucleic acid. Also provided are pharmaceutical compositions comprising a therapeutically effective amount of the lipid nanoparticles encapsulating a therapeutically active polynucleic acid. Also provided are pharmaceutical compositions for delivering the polynucleic acids to lung tissue of a subject.

非糖尿病加齢マウスにおいて創傷の治癒を促進するためのＨｏｘＡ３治療方法

Resumen de: CN120435305A

Chronic wounds are characterized by a persistent, overinflamed environment which hinders the progression of regenerative wound closure. Such chronic wounds are particularly common in diabetic patients, typically requiring distal limb amputation, but also occur in non-diabetic elderly patients. HoxA3 is a member of a somatotype modeling and main regulatory transcription factor homologous frame family, and when the HoxA3 is locally applied as a plasmid wrapped in hydrogel, it has been proved that wound closure of diabetic mice can be accelerated through inducible expression of HoxA3. We now provide an independent repetition of these basis in vivo diabetes wound closure studies, and extend it through minimum dose threshold estimation. Furthermore, the natural healing speeds of the wounds of the elderly non-diabetic mouse and the young diabetic mouse are observed to be similar, which provides power for testing local HoxA3 plasmids in the elderly non-diabetic mouse, and the wound healing is observed to be accelerated again. In these short-term studies, we do not observe any serious adverse reaction with naked eyes or through local histology. The local HoxA3 is an attractive transformation candidate target of a chronic wound whether the local HoxA3 is used as a plasmid or a future alternative form.

免疫応答の調節異常の処置のためのマイクロＲＮＡに基づく粒子

Resumen de: AU2024207086A1

A miRNA-mimic based therapeutic particle is disclosed herein. The particles comprise a synthetic miRNA or mimic of miR-187-3p encapsulated in a lipid nanoparticle (LNP) carrier or synthetic miR-193b-5p inhibitor encapsulated in a lipid carrier or their combination encapsulated in a lipid carrier. The lipid nanoparticle carrier is made up of at least four (4) types of lipids, in which the four (4) types of lipids include a) an ionizable cationic lipid selected to be positively charged in a formulation buffer (pH 4), which binds and protects the negatively charged miRNA, and facilitates endosomal escape, and is neutral in a storage buffer, b) a sterol in the structure of the lipid nanoparticle (LNP)., c) a structural helper lipid selected to contribute to lipid nanoparticle stability and/or enhances endosomal release, and d) a PEGylated-lipid selected such that it stabilizes the therapeutic particle and protects it from opsonization.

眼障害の治療

Resumen de: US2025263455A1

Disclosed herein are methods for preventing or treating non-arteritic anterior ischemic optic neuropathy in a subject by administering to the subject a nucleic acid molecule comprising a nucleic acid sequence encoding OCT4, a nucleic acid sequence encoding SOX2, and a nucleic acid sequence encoding KLF4.

一种二肽-光敏剂分子共组装纳米颗粒及其制备方法与应用

Resumen de: CN121338023A

本发明适用于生物医学技术领域，提供了一种二肽‑光敏剂分子共组装纳米颗粒及其制备方法与应用。本发明先通过阳离子型二苯丙氨酸（CDP）与生物交联剂京尼平自组装形成二肽载体，再与光敏剂分子二氢卟吩e6（Ce6）进行共组装，成功制备出尺寸可控、载药量可控且生物相容性良好的纳米颗粒。该制备方法简单易行，有效解决了传统光敏剂分子Ce6生物相容性差、易聚集的关键问题，不仅能高效递送Ce6，还显著提升了其应用安全性与生物相容性。使Ce6在黑暗条件下几乎无暗毒性，光照下可发挥强效光动力杀伤作用，同时凭借尺寸与载药量的灵活调控优势，大幅提高了Ce6用于肿瘤光动力治疗的可能性与应用潜力。

一种近红外二区聚集诱导发光探针、纳米粒子及制备方法与应用

Resumen de: CN121342846A

本发明公开一种近红外二区聚集诱导发光探针、纳米粒子及制备方法与应用，涉及荧光分子探针技术领域。所述近红外二区聚集诱导发光探针的结构式为：；其中，X1、X2和Y各自独立地选自O、S、Se、Te中的一种；R1，R2和R3各自独立地选自H、F、氰基、三氟甲基、饱和烷烃基中的一种。本发明提供的探针在聚集状态下具有较高的发光效率、光热效率和活性氧生成能力，可实现荧光、光声、光热多模态成像与光热/光动力协同治疗。

一种仿生细胞膜纳米颗粒及其制备方法与在类风湿性关节炎中的应用

Resumen de: CN121337834A

本发明公开了一种仿生细胞膜纳米颗粒及其制备方法与在类风湿性关节炎（RA）治疗中的应用。该纳米颗粒由阳离子脂质体与巨噬细胞膜融合构成，表面修饰叶酸配体用于增强滑膜炎症区域的靶向性，并共载有GSDME siRNA和抗炎代谢物4‑辛基衣康酸（4‑OI）。本发明提供的FA‑MMLNP@siG/4OI系统可实现对炎症巨噬细胞的精准识别和高效递药，一方面通过siRNA抑制GSDME表达、阻断巨噬细胞焦亡，另一方面通过4‑OI激活抑制NF‑κB炎症信号并促进M1向M2型巨噬细胞极化，从而协同缓解RA炎症进程。动物实验结果表明，该纳米颗粒具有良好的靶向富集能力、生物安全性和治疗效果。该发明提供了一种新型仿生纳米递药平台，在RA等以巨噬细胞炎性极化与焦亡为特征的炎症性疾病治疗中具有广泛应用前景。

一种白藜芦醇衍生碳点复合材料及其制备方法与应用

Resumen de: CN121337765A

本发明属于属于纳米医药与生殖医学交叉领域，具体涉及一种白藜芦醇衍生碳点复合材料及其制备方法与应用。所述碳点复合材料由白藜芦醇、（3‑氨基丙基）三乙氧基硅烷和透明质酸制得。该碳点复合材料包含以白藜芦醇为前驱体制备的碳点核心、连接于核心表面的氨基硅烷偶联剂层、及包覆于偶联剂层外的带负电荷的生物相容性聚合物外层。其制备方法包括水热法制备碳点核心、偶联剂层的形成和聚合物外层包覆三步。该复合纳米材料提高了白藜芦醇的水溶性和稳定性，增强了抗氧化和抗纤维化能力，可用于制备治疗子宫内膜损伤、薄型子宫内膜等疾病的药物。

METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING NANO-DELIVERY

Resumen de: US20260014089A1

The present disclosure relates to novel compounds, methods, and cell-targeting formulations, e.g., a lipid nanoparticle (LNP) for targeted delivery to a tissue or a cell type. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features for the formulation and a lipid tail for being incorporated into the bilayer membrane of the formed lipid nanoparticle.

COMPOSITIONS AND METHODS OF MAKING AND USE THEREOF

Resumen de: US20260014091A1

Disclosed herein are compositions and methods of making and use thereof. For example, disclosed herein are pharmaceutical compositions comprising: a plurality of redox-responsive disulfide nanoparticles; and a tyrosine kinase inhibitor encapsulated within each of the redox-responsive disulfide nanoparticles. Also disclosed herein are methods of treating or preventing an ocular injury, disease, or disorder in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a plurality of redox-responsive disulfide nanoparticles and/or any of the pharmaceutical compositions disclosed herein to the subject.

LIPID NANOPARTICLES FOR PROTEIN DELIVERY

Resumen de: US20260014088A1

The present invention relates to lipid nanoparticles for the delivery of proteins and, specifically, to lipid nanoparticles for the intracellular or in vivo delivery of various medicinal proteins such as therapeutic proteins or enzymes for enzyme replacement therapy (ERT). The present invention can be advantageously used for the treatment and prevention of various diseases, including lysosomal storage disorders, by stably and effectively delivering various proteins such as therapeutic proteins or ERT enzymes into cells through lipid nanoparticles.

MILK DERIVED EXOSOMES AND USES THEREOF

Resumen de: US20260014085A1

Described herein are milk exosomes and uses thereof. In some embodiments, the milk exosomes are capable of targeting an injury site or a cancer cell or population thereof. The milk exosomes can contain an exogenous cargo. Described herein are formulations containing the milk exosomes, and optionally, a targeting agent, such as IgG or stimulation of ATP concentration, and/or ADP. Also described herein are methods of delivering a cargo to a target.

IONIZABLE LIPID CONTAINING BIODEGRADABLE ESTER BOND AND LIPID NANOPARTICLES COMPRISING SAME

Resumen de: US20260014075A1

The present disclosure relates to a novel ionizable lipid containing a biodegradable ester bond. The ionizable lipid containing an ester bond, according to the present disclosure, stably delivers an anionic drug when prepared into lipid nanoparticles, and exhibits an excellent effect, in particular, in delivering nucleic acids, and thus can be effectively used in related technical fields such as lipid nanoparticle-mediated gene therapy.

COMPOSITIONS AND METHODS INVOLVING TRANSFORMING EXTRACELLULAR VESICLES

Nº publicación: US20260014078A1 15/01/2026

Solicitante:

MAYO FOUNDATION FOR MEDICAL EDUCATION AND RES [US]
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

Resumen de: US20260014078A1

An extracellular vesicle includes an exogenous therapeutic component. The exogenous therapeutic component can include a therapeutic polypeptide, a polynucleotide that encodes a therapeutic polypeptide, a therapeutic nucleic acid, or a therapeutic agent. In some embodiments, the extracellular vesicle includes an exosome or purified exosome product (PEP).